ARA-290 Research Kit

ARA-290 is studied in laboratory and preclinical research as a model peptide for investigating molecular and cellular pathways. Typical research applications include:

• Receptor interaction assays: Testing peptide binding to erythropoietin-related receptors under controlled lab conditions.
• Signal transduction studies: Monitoring intracellular pathways triggered by peptide–receptor engagement.
• Peptide delivery evaluations: Using the spray kit to compare dispersion, solution stability, and administration techniques.

Molecular pathway modeling: Investigating how the peptide influences metabolic, neural, and inflammatory signaling in vitro or in vivo models.

ARA-290 research spans multiple scientific disciplines:

• Neurobiology: Laboratory investigations into peptide activity in neural signaling and experimental neuropathy models.
• Metabolic research: Studies modeling molecular pathways involved in energy regulation and metabolic signaling.
• Inflammatory pathway research: Experimental studies exploring interactions with oxidative and inflammatory mechanisms.
• Cardiovascular research: Laboratory studies examining peptide interactions with vascular signaling pathways, endothelial cell behavior, and tissue-level inflammatory mechanisms in experimental models.
• Renal research: Experimental investigations into molecular pathways in kidney cells and tissue models.
• Cell survival and cytoprotection studies: Research exploring peptide effects on cellular resilience, stress responses, and tissue-level signaling in controlled experimental systems.

Pain and neuropathic pathway research: Mechanistic studies on sensory neuron signaling and molecular pathways involved in experimental neuropathic models.signaling in controlled experimental systems.

Pain and neuropathic pathway research: Mechanistic studies on sensory neuron signaling and molecular pathways involved in experimental neuropathic models.

The ARA-290 Research Spray Kit contains a synthetic, nonerythropoietic peptide supplied with a precision spray applicator for controlled laboratory investigations. It supports studies into peptide–receptor interactions, signal transduction pathways, and comparative administration models. Designed strictly for research use, the kit enables experiments on molecular, metabolic, neural, and inflammatory pathways while providing a reliable system for evaluating peptide dispersion and solution stability.

1. van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014
2. Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides. 2016
3. Al-Onaizi MA, Thériault P, Lecordier S, Prefontaine P, Rivest S, ElAli A. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain Behav Immun. 2022
4. Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015
5. Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Östenson CG, Kumagai-Braesch M. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation. 2016
6. Mohtavinejad N, Hajiramezanali M, Akhlaghi M, Bitarafan-Rajabi A, Gholipour N. Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iran J Basic Med Sci. 2021
7. Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013
8. Atkins C, Wilson AM. Managing fatigue in sarcoidosis – A systematic review of the evidence. Chron Respir Dis. 2017
9. Liu Y, Luo B, Han F, Li X, Xiong J, Jiang M, Yang X, Wu Y, Zhang Z. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One. 2014
10. Winicki NM, Nanavati AP, Morrell CH, Moen JM, Axsom JE, Krawczyk M, Petrashevskaya NN, Beyman MG, Ramirez C, Alfaras I, Mitchell SJ, Juhaszova M, Riordon DR, Wang M, Zhang J, Cerami A, Brines M, Sollott SJ, de Cabo R, Lakatta EG. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan. Front Cardiovasc Med. 2023